Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases: Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
München
Dr. Dr. (Phd-UCN) J. Lechner
[2022]
|
| Ausgabe: | 1. Auflage |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | "A guide to JawBone Detox" - Umschlag |
| Beschreibung: | 398 Seiten Illustrationen 28 cm x 21 cm, 1626 g |
| ISBN: | 9783931351458 3931351459 |
Internformat
MARC
| LEADER | 00000nam a22000008c 4500 | ||
|---|---|---|---|
| 001 | BV048312936 | ||
| 003 | DE-604 | ||
| 005 | 20221107 | ||
| 007 | t | ||
| 008 | 220705s2022 gw a||| |||| 00||| eng d | ||
| 015 | |a 22,N04 |2 dnb | ||
| 016 | 7 | |a 1249943485 |2 DE-101 | |
| 020 | |a 9783931351458 |c Broschur : EUR 68.00 (DE), EUR 70.00 (AT) |9 978-3-931351-45-8 | ||
| 020 | |a 3931351459 |9 3-931351-45-9 | ||
| 024 | 3 | |a 9783931351458 | |
| 035 | |a (OCoLC)1335401105 | ||
| 035 | |a (DE-599)DNB1249943485 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-19 |a DE-12 | ||
| 084 | |8 1\p |a 610 |2 23sdnb | ||
| 100 | 1 | |a Lechner, Johann |d 1948- |e Verfasser |0 (DE-588)128669268 |4 aut | |
| 245 | 1 | 0 | |a Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases |b Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology |c Dr. Dr. (PhD) Johann Lechner, Dr. Miguel Stanley |
| 250 | |a 1. Auflage | ||
| 264 | 1 | |a München |b Dr. Dr. (Phd-UCN) J. Lechner |c [2022] | |
| 264 | 0 | |a Furth bei Landshut |b MDV Maristen Druck & Verlag GmbH |c [2022] | |
| 264 | 4 | |c © 2022 | |
| 300 | |a 398 Seiten |b Illustrationen |c 28 cm x 21 cm, 1626 g | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a "A guide to JawBone Detox" - Umschlag | ||
| 650 | 0 | 7 | |a Knochennekrose |0 (DE-588)4164292-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kiefer |g Anatomie |0 (DE-588)4030457-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Ultraschalldiagnostik |0 (DE-588)4061557-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Osteolyse |0 (DE-588)4210410-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Entzündung |0 (DE-588)4014975-4 |2 gnd |9 rswk-swf |
| 653 | |a Radiation-free imaging | ||
| 653 | |a Ultrasonography | ||
| 689 | 0 | 0 | |a Entzündung |0 (DE-588)4014975-4 |D s |
| 689 | 0 | 1 | |a Kiefer |g Anatomie |0 (DE-588)4030457-7 |D s |
| 689 | 0 | 2 | |a Osteolyse |0 (DE-588)4210410-5 |D s |
| 689 | 0 | 3 | |a Knochennekrose |0 (DE-588)4164292-2 |D s |
| 689 | 0 | 4 | |a Ultraschalldiagnostik |0 (DE-588)4061557-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Stanley, Miguel |e Verfasser |4 aut | |
| 710 | 2 | |a MDV Maristen Druck & Verlag GmbH |0 (DE-588)1065494211 |4 pbl | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1249943485/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033692453&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033692453 | ||
| 883 | 1 | |8 1\p |a vlb |d 20220120 |q DE-101 |u https://d-nb.info/provenance/plan#vlb | |
Datensatz im Suchindex
| _version_ | 1804184164535107584 |
|---|---|
| adam_text | TABLE
OF
CONTENTS
FOREWORD
BY
DR.
MIGUEL
STANLEY
3
FOREWORD
BY
DR.
JOHANN
LECHNER
5
INTRODUCTION
19
1.
WHAT
ARE
BONE
MARROW
DEFECTS
IN
JAWBONE
?
23
1.1
DIFFERENT
DEFINITIONS
AND
CLASSIFICATIONS
-
A
PLEA
FOR
PRECISE
TERMINOLOGY
25
1.1.1
MAXILLO-MANDIBULAR
OSTEOIMMUNOLOGY
25
1.1.2
NICO
AND
FDOJ
25
1.1.3
SUMMARISING
CONCLUSION
28
1.2
MORPHOLOGY
OF
FATTY
DEGENERATIVE
OSTEOLYSIS/OSTEONECROSIS
IN
JAWBONE
30
1.2.1
MACROSCOPIC
FEATURES
OF
BONE
SAMPLES
30
1.2.2
EXTENT
OF
FDOJ
SHOWN
BY
CONTRAST
AGENT
31
1.2.3
PATHOPHYSIOLOGY
AND
CELL
BIOLOGY
OF
FDOJ
33
1.3
HISTOLOGY
OF
FDOJ
35
1.3.1
PATHOHISTOLOGICAL
DEFINITION
OF
FATTY
DEGENERATIVE
OSTEOLYSIS
OF
JAWBONE
35
1.3.2
ADDITIONAL
HISTOLOGIC
STUDIES
AND
CHARACTERIZING
HISTOLOGIC
FINDINGS
ON
FDOJ
CAN
ALSO
BE
FOUND
IN
CHAPTERS
36
1.3.3
PROF.
JE
BOUQUOT
AND
THE
HISTOLOGY
OF
FDOJ
36
1.4
HOW
TO
MEASURE
RANTES/CCL5
IN
FDOJ
SAMPLES?
37
1.4.1
PROCESSING
OF
NECROTIC
TISSUE
SAMPLES
AND
MEASUREMENT
OF
RANTES
IN
FDOJ
SAMPLES
AND
SERUM
37
1.4.2
ANALYSIS
OF
RANTES
IN
SERUM
38
1.5
FDOJ
AND
RANTES/CCL5
-
PARTNERS
OF
INFLAMMATORY
SYSTEMIC
NETWORKING?
38
1.5.1
FDOJ
AS
A
SYSTEMIC
THREAT
THROUGH
RANTES/CCL5
OVEREXPRESSION
39
1.5.2
THE
ROLE
OF
RANTES/CCL5
IN
DISEASES
39
1.5.3
ORIGIN
OF
RANTES/CCL5
IN
FDOJ:
FATTY
TISSUE
AND
ADIPOCYTES
41
1.6
RESULTS
OF
RANTES/CCL5
AND
FGF-2
OVEREXPRESSION
IN
FDOJ 43
1.6.1
RESULTS
OF
PRELIMINARY
RESEARCH
ON
JAWBONE
CYTOKINE
EXPRESSION
43
1.6.2
STUDY
CONCENTRATING
ON
31
FDOJ
AND
3
HEALTHY
JAWBONE
PATIENTS
44
1.6.3
RANTES
IN
JAWBONE
CAVITATIONS
-
ASSIGNED
TO
CLINICAL
DISEASE
45
1.6.4
FGF-2
IN
JAWBONE
CAVITATION
TISSUE
-
ASSIGNED
TO
CLINICAL
DISEASE
46
1.6.5
CHARACTERISTICS
OF
RANTES/CCL5
47
1.6.6
COMPARISON
OF
RANTES
EXPRESSION
IN
FDOJ
TO
RANTES
EXPRESSION
IN
PATHOLOGICAL
BODY
TISSUES
47
7
1.6.7
CHARACTERISTICS
OF
FGF-2
48
1.6.8
COMPARISON
OF
FGF-2
EXPRESSION
IN
FDOJ
WITH
FGF-2
EXPRESSION
IN
PATHOLOGICAL
BODY
TISSUE
49
1.6.8.1
RANTES
AND
FGF-2
AND
THEIR
ROLE
IN
BREAST
CANCER
50
1.6.8.2
RANTES
AND
FGF-2
AND
THEIR
ROLE
IN
RHEUMATOID
ARTHRITIS
51
1.6.8.3
RANTES
AND
FGF-2
AND
THEIR
ROLE
IN
NEURODEGENERATIVE
DISEASES
52
1.6.9
FDOJ
-
A
LOCAL
SITE
OF
CHRONIC
INFLAMMATION
IN
JAWBONE
53
1.6.10
FDOJ
AREAS
-
A
SYSTEMIC
PATHOGENIC
RELEVANT
PHENOMENON
54
1.6.11
SUMMARY
AND
CONCLUSION
54
1.7
DISCUSSION
OF
THE
IMMUNOLOGICAL
RESULTS
57
1.7.1
INFLAMMATORY
AND
PROINFLAMMATORY
MESSENGERS
57
1.7.2
ANTIINFLAMMATORY
MESSENGERS
57
1.7.3
INFLAMMATORY
BALANCE
IN
FDOJ
58
1.7.4
ORIGIN
OF
RANTES/CCL5
IN
FDOJ
58
1.7.5
SYNOPSIS
59
1.8
ASEPTIC-AVASCULAR
OSTEONECROSIS
-
FDOJ
IN
ICD-1
0?
61
1.8.1
LOCAL
SILENT
INFLAMMATION
IN
THE
JAWBONE
AND
RANTES/CCL5
OVEREXPRESSION
61
1.8.2
METHODS
AND
ANALYSIS
61
1.8.2.1
PCR
DNA
ANALYSIS
OF
THE
EXTRACTED
BONE
SAMPLES
62
1.8.2.2
ANALYSIS
OF
PRESURGICAL
RADIODENSITY
OF
THE
FDOJ
AREA
IN
OPG
62
1.8.2.3
HISTOLOGY
ANALYSIS
OF
24
FDOJ
SAMPLES
63
1.8.2.4
PCR
ANALYSIS
OF
FDOJ
IN
TERMS
OF
BACTERIAL
DNA
63
1.8.2.5
CYTOKINE/CHEMOKINE
ANALYSIS
OF
FDOJ
SAMPLES
64
1.8.2.6
X-RAY
RADIODENSITY
ANALYSIS
OF
FDOJ
AREAS
65
1.8.2.7
CORRELATIONS
BETWEEN
RADIODENSITY
AND
RANTES
LEVELS
IN
FDOJ
SAMPLES
65
1.8.2.8
SUMMARY
OF
RESULTS
66
1.8.3
DISCUSSION
66
1.8.3.1
DISCUSSION
OF
HISTOLOGICAL
RESULTS
66
1.8.3.2
DISCUSSION
OF
RADIODENSITY
WITHIN
THE
FDOJ
AREA
IN
OPG 67
1.8.3.3
DISCUSSION
OF
PCR
ANALYSIS
OF
FDOJ
S
BACTERIAL
DNA
68
1.8.3.4
DISCUSSION
OF
THE
CYTOKINE/CHEMOKINE
ANALYSIS
IN
FDOJ
68
1.8.4
SUMMARY
AND
CONCLUSION
69
8
2.
RANTES
UND
SYSTEMIC
DISEASES
73
2.1
PATHOGENETIC
ASPECTS
OF
FDOJ:
APPROACH
TO
A
MEDIATOR-BASED
HYPOTHESIS
OF
SYSTEMIC-CAUSAL
RELATIONS
73
2.1.1
CHEMOKINE
RANTES/CCL5
AS
AN
UNKNOWN
LINK
BETWEEN
WOUND
HEALING
IN
JAWBONE
AND
SYSTEMIC
DISEASE
73
2.1.1.1
RESULTS
OF
SEVEN
CYTOKINE
PANEL
EVALUATIONS
IN
OSTEONECROTIC
AND
HEALTHY
JAWBONE
74
2.1.1.2
EXPRESSION
OF
SEVEN
CYTOKINES
IN
THE
WISDOM
TOOTH
AREA
OF
JAWBONE
IN
16
PATIENTS
WITH
RHEUMATIC
ARTHRITIS
74
2.1.1.3
CASE
REPORT:
RANTES
OVEREXPRESSION
IN
JAWBONE
IN
THE
FORMER
WISDOM
TOOTH
AREA
75
2.1.1.4
EXPRESSION
OF
SEVEN
CYTOKINES
IN
THE
APICAL
AREA
OF
ROOT-FILLED
TEETH
IN
JAWBONE
75
2.1.1.5
CASE
REPORT:
RANTES
OVEREXPRESSION
IN
JAWBONE
UNDERNEATH
A
ROOT-FILLED
TOOTH
76
2.1.1.6
CASE
REPORT:
RECURRING
BREAST
CANCER
AND
COMPARISON
OF
RANTES
OVEREXPRESSION
IN
THE
WISDOM
TOOTH
AREA
AND
IN
JAWBONE
UNDERNEATH
A
ROOT-FILLED
TOOTH
77
2.1.1.7
CONCLUSIONS
78
2.1.2
HYPERACTIVATED
SIGNALING
PATHWAYS
OF
CHEMOKINE
RANTES/CCL5
IN
OSTEOPATHIES
OF
JAWBONE
IN
BREAST
CANCER
PATIENTS
79
2.1.2.1
COHORT
OF
23
BREAST
CANCER
PATIENTS
79
2.1.2.2
RESULTS
OF
7
CYTOKINE
PANEL
EVALUATION
IN
OSTEONECROTIC
AND
HEALTHY
JAWBONE
79
2.1.2.3
THE
ROLE
OF
RANTES
IN
DISEASES
81
2.1.2.4
ROLE
OF
RANTES
IN
BREAST
CANCER
81
2.1.2.5
ORIGIN
OF
RANTES
IN
FDOJ:
FATTY
TISSUE
AND
ADIPOCYTES
82
2.1.2.6
COMPARISON
OF
RANTES
EXPRESSION
IN
FDOJ
TO
RANTES
EXPRESSION
IN
BREAST
CANCER
TISSUES
82
2.1.2.7
RANTES
AND
METASTASIS
OF
BREAST
CANCER
83
2.1.2.8
RANTES/CCL5
IN
SERUM
AND
CORRELATION
TO
BREAST
CANCER
83
2.1.2.9
FDOJ
AND
RANTES
-
PARTNERS
OF
INFLAMMATORY
SYSTEMIC
NETWORKING?
84
2.1.2.10
SYNOPSIS
AND
CONCLUSION
85
2.1.3
CASE
STUDIES
LINKING
SILENT
INFLAMMATION
IN
JAWBONE
WITH
EPISTEMOLOGY
OF
BREAST
CANCER
88
2.1.3.1
CRITICAL
INTERPLAY
OF
JAWBONE
CAVITATIONS
EXPRESSED
RANTES/CCL5
ON
BREAST
CANCER?
88
2.1.3.2
SILENT
INFLAMMATION
IN
JAWBONE:
CLINICAL
FEATURES
OF
FATTY-DEGENERATIVE
OSTEONECROSIS
JAWBONE
-
DEFINITION
AND
DIAGNOSTIC
CRITERIA
88
2.1.3.3
STUDY
PARTICIPANTS:
39
FEMALE
PATIENTS
WITH
BREAST
CANCER
90
2.1.3.4
IMMUNOHISTOCHEMISTRY
OF
RANTES/CCL5
EXPRESSION
IN
FDOJ
90
9
2.1.3.5
MULTIPLEX
ANALYSIS
OF
39
FDOJ
SAMPLES
IN
BREAST
CANCER
CASES
-
RANTES/
CCL5
EXPRESSION
WHEN
COMPARED
TO
HEALTHY
JAWBONE
90
2.1.3.6
CLINICAL
CASES
OF
2
BREAST
CANCER
PATIENTS
-
COMPARISON
OF
X-RAY
DIAGNOSTICS,
RANTES/CCL5
EXPRESSION
AND
LIGHT
MICROSCOPY.
91
2.1.3.7
IMMUNOHISTOCHEMISTRY
AND
STAINING
OF
RANTES/CCL5
EXPRESSION
IN
JAWBONE
IN
TWO
BREAST
CANCER
PATIENTS
93
2.1.3.8
IMMUNOHISTOCHEMISTRY
AND
STAINING
OF
BREAST
CANCER
PREPARATIONS
94
2.1.3.9
RANTES/CCL5
IN
FDOJ
SAMPLES
VERSUS
SERUM
SAMPLES
95
2.1.3.10
ADIPOSE
TISSUE
AND
RANTES/CCL5
IN
OBESITY,
IN
BREAST
CANCER
AND
IN
FDOJ
97
2.1.3.11
THE
ROLE
OF
ADIPOCYTES
AND
RANTES/CCL5
IN
TUMOR
GROWTH
AND
PROLIFERATION
99
2.1.3.12
HIGH
SERUM
LEVELS
OF
RANTES/CCL5
SERVE
AS
INDICATOR
IN
TUMORIGENESIS
AND
PERPETUATE
ANGIOGENESIS
IN
THE
TUMOR
101
2.1.3.13
ADIPOCYTES
IN
TUMOR
AND
IN
FATTY-DEGENERATED
JAWBONE
MARROW
ARE
THE
SOURCE
OF
RANTES/CCL5
EXPRESSION
101
2.1.3.14
RANTES/CCL5
AND
BREAST
CANCER
METASTASIS
102
2.1.3.15
CONCLUSION:
IMMUNE
SYSTEM
-
BONE
INTERACTIONS
IN
THE
NEW
FIELD
OF
MAXILLO-MANDIBULAR
OSTEOIMMUNOLOGY
102
2.1.4
CASE
REPORTS:
METASTASIS
OF
BREAST
CANCER
ADENOCARCINOMA
IN
JAWBONE/FDOJ
108
2.1.4.1
CASE
#1:
108
2.1.4.2
CASE
#2:
109
2.1.4.3
CONCLUSION
111
2.1.5
PERIPHERAL
NEUROPATHIC
FACIAL/TRIGEMINAL
PAIN
AND
RANTES/CCL5
IN
JAWBONE
CAVITATION
111
2.1.5.1
ETIOLOGY
OF
CHRONIC
FACIAL
PAIN
111
2.1.5.2
PATIENT
COHORT:
15
PATIENTS
WITH
AFP/TRN
112
2.1.5.3
SAMPLING
OF
FDOJ
TISSUE
ON
15
PATIENTS
WITH
AFP/TRN
113
2.1.5.4
RESULTS
113
2.1.5.5
HISTOLOGY
IN
NEUROPATHIC
FACIAL
PAIN
114
2.1.5.6
HYPERACTIVATED
CHEMOKINE
RANTES/CCL5
IN
FDOJ
114
2.1.5.7
IMMUNOLOGY
IN
NEUROPATHIC
FACIAL
PAIN
115
2.1.5.8
OPIOID
RECEPTORS
AND
CHEMOKINE
RANTES/CCL5
116
2.1.5.9
DIAGNOSTIC
PROBLEMS
OF
FDOJ
LESIONS
BY
X-RAY
117
2.1.5.10
CLINICAL
RELEVANCE
OF
FDOJ
SURGERY
IN
AFP/TRN
CASES
118
2.1.5.11
CLINICAL
CASE
OF
FDOJ
SURGERY
119
2.1.5.12
CONCLUSIONS
120
2.1.6
THE
IMPACT
OF
RANTES
FROM
JAWBONE
ON
CHRONIC
FATIGUE
SYNDROME
123
2.1.6.1
METHODS:
21
PATIENTS
WITH
CCHRONIC
FATIGUE
SYNDROME
123
10
2.1.6.2
RESULTS:
21
CHRONIC
FATIGUE
SYNDROME
PATIENTS
124
2.1.6.3
DISCUSSION
125
2.1.6.4
CONCLUSION:
THE
CHRONIC
FATIGUE
SYNDROME
INFLAMMATORY
HYPOTHESIS
126
2.1.7
THE
VITAMIN
D
RECEPTOR
AND
THE
ETIOLOGY
OF
RANTES/CCL-EXPRESSIVE
FATTY-DEGENERATIVE
OSTEOLYSIS
OF
THE
JAWBONE
129
2.1.7.1
AN
INTERFACE
BETWEEN
OSTEOIMMUNOLOGY
AND
BONE
METABOLISM
129
2.1.7.2
STUDY
COHORT
OF
43
PATIENTS
WITH
FDOJ
129
2.1.7.3
SERUM
MEASUREMENT
OF
25D
AND
1
,25D
130
2.1.7.4
CYTOKINE
PROFILE
MEASUREMENT
IN
JAWBONE
OSTEOLYSIS
130
2.1.7.5
DISTRIBUTION
OF
1,25D
AND
25D
IN
THE
TOTAL
COHORT
131
2.1.7.6
THE
RATIO
OF
25-HYDROXY-(CHOLECALCIFEROL)
AND
1
,25-DIHYDROXY-(CALCITRIOL)
VITAMIN
D3
IN
THE
DETERMINATION
OF
A
DEACTIVATED
VITAMIN
D
RECEPTOR
132
2.1.7.7
RANTES
EXPRESSION
AND
THE
VITAMIN
D
RATIO
134
2.1.7.8
SERUM
LEVELS
OF
1
,25D
AND
25D
IN
THE
FDOJ
COHORT
134
2.1.7.9
THE
PHENOMENON
OF
THE
DEACTIVATED
VITAMIN
D
RECEPTOR
135
2.1.7.10
THE
CONNECTION
BETWEEN
DEACTIVATED
VDR
AND
FDOJ:
DISRUPTED
VITAMIN
D
METABOLISM
AND
PATHOLOGICAL
MORPHOLOGY
IN
THE
JAWBONE
135
2.1.7.11
SYSTEMIC
SIGNAL
TRANSDUCTION
BY
HYPERACTIVATED
RANTES/CCL5
FROM
FDOJ
AREAS
136
2.1.7.12
SYSTEMIC
CROSS-LINKING
OF
VDR
DEACTIVATION
AND
OSTEOLYSIS
IN
THE
JAWBONE
137
2.1.7.13
CONCLUSIONS
139
2.2
SALUTOGENETIC
ASPECTS
OF
FDOJ
TREATMENT
IN
COMPLEMENTARY
MEDICAL
PRACTICE
143
2.2.1
CLINICAL
CASE
REPORT
#1:
MALE
PATIENT,
AGE
38:
RHEUMATIC
JOINT
PAIN
143
2.2.1.2
POSTSURGICAL
FINDINGS
AFTER
FDOJ
DEBRIDEMENT
143
2.2.1.3
HISTOLOGICAL
FINDINGS
143
2.2.1.4
EVALUATION
OF
PATHOLOGIC
ANALYSIS
DATA
144
2.2.2
CLINICAL
CASE
REPORT
#1:
MALE
PATIENT,
AGE
39:
ASTHMA
144
2.2.2.1
CLINICAL
SYMPTOMS
144
2.2.2.2
POSTSURGICAL
FINDINGS
AFTER
FDOJ
TREATMENT
144
2.2.2.3
HISTOLOGICAL
FINDINGS
144
2.2.2.4
EVALUATION
OF
PATHOLOGIC
ANALYSIS
DATA
145
2.2.3
CASE
STUDY
LINKING
RANTES/CCL5
OVEREXPRESSION
IN
JAWBONE
WITH
CHEMOKINE
RECEPTORS
IN
THE
CENTRAL
NERVOUS
SYSTEM.
145
2.2.3.1
SILENT
INFLAMMATION
IN
THE
JAW
AND
NEUROLOGICAL
DYSREGULATION
145
2.2.3.2
THE
CLINICAL
CASE:
19-YEAR-OLD
FEMALE
PATIENT
145
2.2.3.3.
SUMMARY
OF
CLINICAL
INVESTIGATIONS,
FINDINGS,
AND
TREATMENTS
146
2.2.3.4
DIAGNOSIS
OF
SILENT
INFLAMMATION
IN
THE
JAW
146
11
147
2.2.3.5
HYPERACTIVATED
IMMUNE
MEDIATORS
IN
OSTEOLYTIC
JAWBONE
2.2.3.6
HISTOLOGY
OF
FDOJ
SURGICAL
AREAS
148
2.2.3.7
RESULTS
OF
JAWBONE
REMEDIATION
FROM
MARCH
2010
TO
AUGUST
2010
IN
THE
CASE
OF
RECURRENT
SYNCOPE
148
2.2.3.8
TRANSITION
FROM
ACUTE
WOUND
INFECTION
TO
CHRONIC
INFLAMMATION
150
2.2.3.9
SYSTEMIC
EFFECTS
OF
THE
CHEMOKINE
RANTES/CCL5
151
2.2.3.10
FDOJ
AREAS
BECOME
IMMUNOLOGICALLY
EFFECTIVE
NEO-SELF
EPITOPES
151
2.2.3.11
CHEMOKINE-INDUCED
SILENT
INFLAMMATION
IN
THE
CENTRAL
NERVOUS
SYSTEM
152
2.2.3.12
CONCLUSION
-
LINK
BETWEEN
THE
JAWBONE
AND
THE
CENTRAL
NERVOUS
SYSTEM
153
2.2.4
CHRONIC
FATIGUE
SYNDROME
AND
SILENT
INFLAMMATION
OF
THE
JAW
157
2.2.4.1
CASE
STUDY
ON
SUPPLEMENTING
DIAGNOSTIC
DENTAL
X-RAYS
WITH
ULTRASOUND
157
2.2.4.2
RADIOLOGICAL
FINDINGS
WITH
2D-OPG
AND
DVT/CBCT
157
2.2.4.3
TRANS-ALVEOLAR
ULTRASOUND
BONE
DENSITY
MEASUREMENT
158
2.2.4.4
SURGICAL
REPAIR
OF
AREA
38/39
159
2.2.4.5
BONE
MARROW
DEFECT
MORPHOLOGY
160
2.2.4.6
HISTOLOGICAL
FINDINGS
160
2.2.4.7
LOCAL
HYPERACTIVATION
OF
IMMUNE
MEDIATOR
CHEMOKINE
RANTES/CCL5
IN
OSTEOLYTIC
JAWBONE
160
2.2.4.8
CAVITAU
MEASUREMENT
OF
BONE
DENSITY
161
2.2.4.9
RANTES/CCL5
EXPRESSION
IN
CAVIATION
48/49
161
2.2.4.10
FUNGAL
TOXINS
161
2.2.4.11
CONCLUSION
162
2.3.1
OSTEOIMMUNOLOGY
OF
TUMOR
NECROSIS
FACTOR-ALPHA,
LNTERLEUKIN-6,
AND
RANTES/CCL5
165
2.3.1.1
A
REVIEW
OF
KNOWN
AND
POORLY
UNDERSTOOD
INFLAMMATORY
PATTERNS
IN
OSTEONECROSIS
165
2.3.1.2
TNF-A
AND
IL-6
IN
INFLAMMATORY
BONE
DEGRADATION
165
2.3.1.3
BONE
RESORPTION
BY
TNF-A
AND
IL-6
IN
RHEUMATOID
ARTHRITIS
166
2.3.1.4
BONE
RESORPTION
BY
TNF-A
AND
IL-6
IN
OSTEOPOROSIS
167
2.3.1.5
THE
ROLE
OF
TNF-A
AND
IL-6
IN
OBESITY
168
2.3.1.6
THE
ROLE
OF
TNF-A
AND
IL-6
IN
MAXILLO-MANDIBULAR
BONE
RESORPTION
AND
INFLAMMATORY
ORAL
MEDICAL
CONDITIONS
169
2.3.1.7
IN
BONE
RESORPTION
-
EXCEPT
FOR
FDOJ
-
TNF-A
IS
THE
PRIMARY
INFLAMMATORY
CYTOKINE
176
2.3.1.8
CONCLUSION
FDOJ
AS
AN
UNIQUE
INFLAMMATORY
EVENT
177
2.3.2
IMMUNOHISTOLOGICAL
STAINING
OF
UNKNOWN
CHEMOKINE
RANTES/CCL5
EXPRESSION
IN
JAWBONE
MARROW
DEFECTS
182
12
2.3.2.1.
OSTEOIMMUNOLOGY
AND
DISRUPTION
OF
BONE
REMODELING
IN
CLINICAL
CASE
STUDIES
182
2.3.2.2
COMPARISON
OF
X-RAY
DIAGNOSTICS,
RANTES/CCL5
EXPRESSION,
LIGHT
MICROSCOPY,
AND
IMMUNOHISTOCHEMISTRY
IN
SIX
CLINICAL
CASES
185
2.3.2.3
SUMMARY
OF
RESULTS
189
2.3.2.4
CONCLUSIONS
-
MAXILLO-MANDIBULAR
OSTEOIMMUNOLOGY
-
INTERACTIONS
BETWEEN
BONE
AND
THE
IMMUNE
SYSTEM.
193
3.
DIAGNOSTIC
PROBLEMS
OF
BMDJ/FDOJ
LESIONS
IN
JAWBONE
197
3.1
DETERMINING
BONE
DENSITY
IN
THE
JAW
AND
LOCATION
OF
BONE
MARROW
DEFECTS
199
3.1.1
WHY
IS
A
PANORAMIC
X-RAY
(2D-OPG)
NOT
ENOUGH
FOR
THE
DIAGNOSIS
OF
A
BONE
MARROW
DEFECT
?
199
3.1.2
OTHER
METHODS
FOR
IMAGING
BONE
STRUCTURES
200
3.1.2.1
COMPUTED
TOMOGRAPHY
200
3.1.2.2
CONE
BEAM
CT/DIGITAL
VOLUME
TOMOGRAPHY
(CBCT/DVT):
201
3.1.2.3
MAGNETIC
RESONANCE
IMAGING
(MRI)
201
3.1.2.4
TECHNETIUM-99M
RADIOISOTOPE
SCINTIGRAPHY
202
3.1.3
CLASSIFICATION
OF
BONE
DENSITY
WITH
HOUNSFIELD
UNITS
202
3.2
VALIDATION
OF
DENTAL
X-RAY
BY
CYTOKINE
RANTES
207
3.2.1
COMPARISON
OF
X-RAY
FINDINGS
WITH
CYTOKINE
RANTES
OVEREXPRESSION
IN
JAWBONE
207
3.2.2
GROUPS
OF
PATIENTS
EXAMINED
207
3.2.3
RELIABILITY
OF
INFORMATION
ON
X-RAY
DENSITY
OF
X-RAY
MACHINE
USED
207
3.2.4
ULTRASOUND
MEASUREMENT
OF
BONE
DENSITY
-
TRANSALVEOLAR
ULTRASOUND
MEASUREMENT
207
3.2.5
REFERENCE
VALUES
FOR
VALIDATING
THE
X-RAY
DENSITY
208
3.2.5.1
IMMUNE
MESSENGERS
AND
X-RAY
DENSITY
OF
HEALTHY
JAWBONE
(N
=
19)
209
3.2.5.2
HYPERACTIVATED
CHEMOKINE
RANTES/CCL5
IN
FDOJ
209
3.2.5.3
MEASUREMENT
OF
JAWBONE
DENSITY
WITH
TRANSALVEOLAR
ULTRASOUND
TECHNOLOGY
(TAU)
210
3.2.5.4
COMPARISON
OF
XRDN
AND
RANTES
EXPRESSION
IN
HEALTHY
JAWBONE
(N
=
19)
AND
FDOJ
(N
=
31)
211
3.2.5.5
COMPARISON
OF
XRDN
AND
FDOJ
USING
CONTRAST
AGENT
212
3.2.5.6
INDIVIDUAL
CASE
COMPARING
PREOPERATIVE
AND
POSTOPERATIVE
2D-OPG
WITH
RANTES/CCL5
EXPRESSION
IN
FDOJ
213
3.2.5.7
COMPARISON
OF
XRDN
IN
CONTROLS
WITH
PREOP/
POSTOP
2D-OPG,
WITH
RANTES
EXPRESSION
AND
WITH
TAU
214
3.2.6
CONCLUSIONS
AND
SUMMARY
215
13
4.
ULTRASOUND
IN
DENTISTRY
FOR
MEASURING
BONE
QUALITY
217
4.1
.FUNDAMENTAL
SUITABILITY
OF
QUANTITATIVE
ULTRASOUND
TRANSMISSION
VELOCITY
217
4.2
NON-INVASIVE
ASSESSMENT
OF
THE
HUMAN
JAWBONE
WITH
ULTRASOUND
WAVES
217
4.3
ULTRASOUND
AND
ASSESSMENT
OF
MECHANICAL
BONE
QUALITY
220
4.4
LITERATURE
ON
ULTRASOUND
AND
CAVITATIONS
AND
OSTEONECROSES
OF
THE
JAWBONE
224
4.5
JAWBONES
AND
IMPLANT
STABILITY
-
LITERATURE
ON
ULTRASOUND
TRANSMISION
VELOCITY
(UTV)
FOR
PROSPECTIVE
REVIEW
228
4.6
COMPARISON
OF
PREVIOUS
CAVITAT
TAU
DEVICE
WITH
NEW
CAVITAU
230
4.6.1
HISTORY
OF
TRANS-ALVEOLAR
ULTRASONOGRAPHY
230
4.6.2
TRANSMISSION
ULTRASONOGRAPHY
WITH
OLD
CAVITAT
231
4.6.3
DISADVANTAGES
OF
CAVITAT
231
4.6.4
DESCRIPTION
OF
NEW
CAVITAU
232
4.6.5
NEW
CAVITAU
TECHNOLOGY
FOR
NON-INVASIVE
ASSESSMENT
OF
THE
HUMAN
JAWBONE
WITH
ULTRASOUND
WAVES
233
4.6.6
CAVITAU
DASHBOARD
DISPLAY
235
4.6.7
DETERMINATION
OF
NUMERICAL
BONE
DENSITY
WITH
CAVITAU
236
4.6.8
SEMI-SOLID
GEL
IN
CAVITAU:
ACOUSTIC
COUPLING
237
4.7
TECHNICAL
FEATURES
OF
CAVITAU
238
4.7.1
HOW
ACCURATE
IS
CAVITAU?
239
4.7.2
ARE
CAVITAU
MEASUREMENTS
REPRODUCIBLE?
244
5.
HOW
TO
USE
CAVITAU
IN
PRAXIS
247
5.1
LATERAL
CONTROL
CAVITAU
MEASUREMENT
249
5.2
VERTICAL
CONTROL
CAVITAU
MEASUREMENT
250
5.2.1
3-STEP
MEASUREMENT
OF
THE
LOWER
JAW
WITH
CAVITAU
250
5.2.2
3-STEP
MEASUREMENT
OF
THE
UPPER
JAW
WITH
CAVITAU
251
5.3
CALIBRATING
CAVITAU
253
5.4
CHECKING
CAVITAU
WHEN
TAKING
MEASUREMENTS
254
5.5
VISUALISATION
OF
WATER
AND
AIR
IN
CAVITAU
254
5.6
VISUALISATION
OF
SOFT
TISSUE
IN
CAVITAU
255
5.7
CAVITAU
ENABLES
THE
DENTIST
TO
IMAGE
THE
JAWBONE
WITHOUT
RADIATION
EXPOSURE
259
5.7.1
WHAT
IS
THE
ALARA
PRINCIPLE?
259
5.7.2
WHY
ALARA
PRINCIPLE
IN
DENTISTRY?
260
5.8
CAVITAU
AND
THE
ALARA
PRINCIPLE
IN
THE
DIAGNOSIS
OF
BMDJ
/
FDOJ
I
AOJ
261
5.9
CAVITAU
AND
THE
ALARA
PRINCIPLE
IN
MONITORING
TREATMENT
RESULTS
AND
OPTIMAL
WOUND
HEALING
OF
BMDJ
/
FDOJ
/
AOJ
261
14
6.
WHY
IS
CAVITAU
NECESSARY
IN
DENTISTRY?
263
6.0
WHY
USE
CAVITAU
IN
PRACTICE?
264
6.1
CAVITAU
DISPLAYS
JAWBONE
AREAS
WITH
REDUCED
MINERALISATION
DENSITY
-
265
6.1.1
WHY
WAS
CAVITAU
USED
IN
THESE
SEVEN
CLINICAL
CASES?
265
6.1.2
INDIVIDUAL
EXAMPLES
WITH
RANTES/CCL5
OVEREXPRESSION
271
6.1.3
CAVITAU
SHOWS
AREAS
WITH
IMPAIRED
WOUND
HEALING
276
6.1.4
CAVITAU
SHOWS
AREAS
WITH
OPTIMAL
WOUND
HEALING
276
6.2
IMPLANT
SURGERY,
BONE
MARROW
DEFECTS
IN
THE
JAW
AND
TAU
-
IMPLANT
SUCCESS
WITH
CAVITAU
278
6.2.1
QUESTION
#1
ON
IMPLANT
INSERTION:
IS
THE
JAWBONE
READY
FOR
IMPLANT
INSERTION?
278
6.2.2
QUEST
FOR
ROUTINE
IMPLANT
PRACTICE
AND
CAVITAU
279
6.2.3
THE
PROBLEM:
DETERMINING
THE
BONE
QUALITY
WITH
X-RAY
TECHNIQUES:
A
CRITICAL
OVERVIEW
279
6.2.4
THE
SOLUTION:
DETERMINING
IF
THE
BONE
BEDDING
IS
SECURE
WITH
ULTRASOUND
CAVITAU
280
6.2.5
SUMMARISING
THE
MEDICAL
SIGNIFICANCE
OF
CAVITAU
FOR
IMPLANT
INSERTION
IN
THE
JAW:
HOW
TO
FORECAST
THE
SUCCESS
OF
DENTAL
IMPLANTS?
281
6.2.6
QUESTION
#1
ON
IMPLANT
INSERTION:
DOES
CAVITAU
DISPLAY
LOAD-FREE
JAWBONES
FOR
NON
PROBLEMATIC
AND
DURABLE
IMPLANT
INSERTION?
282
6.2.7
QUESTION
#2
ON
IMPLANT
INSERTION:
SHOULD
I
PLACE
IMPLANTS
IN
POORLY
HEALED
JAWBONES?
284
6.2.8
QUESTION
#3
ON
IMPLANT
INSERTION:
WHY
DO
IMPLANTS
FAIL?
285
6.2.9
QUESTION
#4
ON
IMPLANT
INSERTION:
IS
THERE
A
CONNECTION
BETWEEN
IMPLANT
INSERTION
AND
OCCURRENCE
OF
FDOJ?
287
6.2.9.1
CLINICAL
EXAMPLE:
CAN
THE
RANTES/CCL5
EXPRESSION
BE
RESPONSIBLE
FOR
MULTIPLE
PATIENT
ALLERGIES?
287
6.2.9.2
WHY
DOES
FDOJ
DEVELOP
AROUND
IMPLANTS?
288
6.2.9.3
CAVITAU
DETECTS
FOCAL
INFLAMMATION
AREAS
AROUND
IMPLANTS
THAT
CANNOT
BE
IDENTIFIED
BY
X-RAYS.
290
6.2.10
QUESTION
#5
ON
IMPLANT
INSERTION:
ARE
THERE
AREAS
OF
BONE
AROUND
IMPLANTS
WITH
SPECIFIC
SYSTEMICALLY
RELEVANT
IMMUNE
OR
CYTOKINE
PATTERNS?
293
6.2.10.1
WHY
IS
THIS
PHENOMENON
A
MYSTERY
IN
DENTISTRY?
294
6.2.10.2
WHERE
IS
THE
LINK
BETWEEN
RANTES/CCL5
OVEREXPRESSION
IN
FDOJ
TO
SYSTEMIC
DISEASES?
294
6.2.10.3
IMPLANT
INSERTION
AND
POSSIBLE
CYTOKINE
CASCADES
295
6.2.10.4
CONCLUSIONS
297
6.2.11
RANTES/CCL5
EXPRESSION
IN
20
CASES
WITH
TITANIUM
IMPLANTS
297
6.2.12
CASE
REPORTS
ON
CHRONIC
INFLAMMATION
AROUND
IMPLANTS
AND
CAVITAU
VISUALISATION
298
6.3
ENDODONTICS
AND
CAVITAU
314
6.3.1
IS
ENDODONTIC
TREATMENT
ALWAYS
SAFE?
314
15
6.3.2
CASE
REPORTS
OF
ENDODONTICS
AND
CAVITAU
315
6.3.2.1
CASE
#1:
THE
FIRST
CASE
PERFECTLY
ILLUSTRATES
THE
REQUIREMENT
FOR
A
RADIATION-FREE
METHOD
FOR
OBTAINING
A
VISUAL
REPRESENTATION
OF
THE
MEDULLARY
BONE
DENSITY
IN
PRACTICE.
315
6.3.2.2
CASE
#2:
CAVITAU
SHOWS
OSTEOLYTIC
INTRA
RADICULAR
SEPTA
316
6.3.2.3
CASE
#3:
PATIENT
WITH
RECURRENT
BREAST
CANCER
316
6.3.2.4
CASE
#4:
VISUALISATION
OF
CIRCO-RADICULAR
OSTEOLYSIS/OSTEONECROSIS
WITH
CONTRAST
MED
I
U
M
317
6.3.2.5
CASE
#5:
FEMALE
PATIENT,
HAS
SUFFERED
FROM
FATIGUE
AND
DEPRESSION
FOR
10
YEARS.
318
6.3.2.6
CASE
#6:
THREE
VERTICAL
COMPARATIVE
MEASUREMENTS
319
6.3.2.7
CASE
#7:
THREE
VERTICAL
COMPARATIVE
MEASURING
STEPS
320
6.3.2.8
CASE
#8:
ROOT
FILLING
WITH
PERSISTENT
APICAL
PAIN
320
6.3.2.9
CASE
#9:
DVT/CBCT
DID
NOT
SHOW
ANY
FINDINGS
IN
CHRONIC
PAIN
321
6.4
CAVITAU
FOR
METALLIC
FOREIGN
BODIES
IN
THE
JAW
322
6.4.1
CAVITAU
SHOWS
THE
INFLAMMATORY
EFFECTS
OF
DIFFUSED
METAL
IONS
322
6.4.2
MERCURY
DIFFUSES
INTO
THE
JAWBONE:
A
SCIENTIFIC
STUDY
BY
THE
UNIVERSITY
OF
VIENNA
325
6.5
BONE
REGENERATION,
BONE
GRAFTING
AND
CAVITAU
326
6.5.1
CASE
#1:
MEDICAL
HISTORY:
CHRONIC
BRONCHITIS,
CHRONIC
PAIN
IN
THE
LEFT
MAXILLARY
SINUS
WITH
MORNING
SPUTUM.
326
6.5.2
CASE
#2:
MALE
PATIENT,
49
YEARS
OLD:
SMALL
FIBRE
NEUROPATHY
WITH
CONSTANT
BURNING
FEELING
IN
HANDS
AND
FEET.
330
6.6
OSTEONECROSIS
OF
THE
JAW
BEYOND
BISPHOSPHONATES:
ARE
THERE
ANY
UNKNOWN
LOCAL
RISK
FACTORS?
332
6.6.1
RESEARCH
QUESTION
332
6.6.2
MATERIAL
AND
METHODS
332
6.6.3
BISPHOSPHONATES
AND
ANTITUMOR
THERAPY
333
6.6.3.1
BISPHOSPHONATES
AND
MESENCHYMAL
STEM
CELLS
333
6.6.3.2
BISPHOSPHONATES
AND
ANTI-ANGIOGENESIS
333
6.6.4
OSTEOIMMUNOLOGICAL
PARAMETERS
OF
AIOJ/BMD/FDOJ
AND
BRONJ
WITH
THE
SAME
IMPACT
IN
RESPONSE
TO
BPS
334
6.6.4.1
RANTES/CCL5:
OVEREXPRESSION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
334
6.6.4.2
ISCHEMIA
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
335
6.6.4.3
OSTEOBLAST
ACTIVATION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
336
6.6.4.4
OSTEOCLAST
DEACTIVATION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
337
16
6.6.4.5
ALKALINE
PHOSPHATASE
REDUCTION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
337
6.6.5
OSTEOIMMUNOLOGICAL
PARAMETERS
OF
AIOJ/BMD/FDOJ
AND
BRONJ
WITH
REVERSED
EFFECTS
AFTER
BP
TREATMENT
338
6.6.5.1
RANKL
DISORDER
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
338
6.6.5.2
OSTEOPROTEGERIN
DISORDER
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
338
6.6.5.3
COMMON
DIAGNOSTIC
PARAMETERS
OF
AIOJ/BMD/FDOJ
AND
BRONJ
339
6.6.5.4
HISTOPATHOLOGY
AS
A
COMMON
FEATURE
OF
BRONJ
AND
AIOJ/BMD/FDOJ
339
6.6.6
CASE
DESCRIPTION
OF
AIOJ/BMD/FDOJ
AND
NON-EXPOSED
BRONJ.
339
6.6.7
DISCUSSION
340
6.6.8
CONCLUSION
342
7.
WHY
IS
CAVITAU
IMPORTANT
FOR
SYSTEMIC
DISEASES?
345
7.1
TRIGEMINAL
NEURALGIA,
ATYPICAL
FACIAL
PAIN
AND
CAVITAU
346
7.1.1
TO
SET
THE
MOOD:
PROBABLY
THE
MOST
PAINFUL
CONDITION
IN
THE
WORLD
346
7.1.2
LITERATURE
ON
THE
MEDICAL
IMPORTANCE
OF
TAU
IN
THE
DIAGNOSIS
AND
TREATMENT
OF
TRIGEMINAL
NEURALGIA
AND
ATYPICAL
FACIAL
PAIN
347
7.1.3
CASE
REPORTS
OF
TRIGEMINAL
NEURALGIA/
ATYPICAL
FACIAL
PAIN
AND
CAVITAU
348
7.2
NEURODEGENERATIVE
DISEASES
AND
CAVITAU
358
7.2.1
NEURODEGENERATIVE
DISEASES:
AMYOTROPHIC
LATERAL
SCLEROSIS,
RANTES/CCL5
AND
CAVITAU
360
7.2.2
NEURODEGENERATIVE
DISEASES:
MULTIPLE
SCLEROSIS
(MS)
AND
CAVITAU
365
7.3
CHRONIC
FATIGUE
SYNDROME
AND
CAVITAU
368
7.3.1
CHRONIC
FATIGUE
SYNDROME
AND
HYPERACTIVATED
IMMUNE
SIGNALS
RANTES/CCL5
FROM
THE
JAWBONE:
SCIENTIFIC
STUDY
368
7.3.2
CAVITAU
CASE
REPORTS
AND
CHRONIC
FATIGUE
SYNDROME
374
7.3.2.1
CASE
#1:
REDUCING
CHRONIC
FATIGUE
TO
AN
ALMOST
NORMAL
LEVEL
374
8.
PUBLISHED
PAPERS
ON
CAVITAU
377
8.1
ULTRASOUND
SONOGRAPHY
CAVITAU
TO
DETECT
FOCAL
OSTEOPOROTIC
JAWBONE
MARROW
DEFECTS
377
8.1.1
METHODS
FOR
VALIDATION
OF
CAVITAU
MEASUREMENTS
377
8.1.2
COMPARISON:
CAVITAU
VS
HISTOLOGY
OF
BMD/FDOJ
377
8.1.3
COMPARISON:
CAVITAU
IN
FATTY
DEGENERATIVE
OSTEOLYSIS
(IN
JAWBONE
WITH
REDUCED
BONE
DENSITY)
VERSUS
LOCAL
RANTES/CCL5
OVEREXPRESSION
378
8.2
FOCAL
BONE
MARROW
DEFECTS
IN
THE
JAWBONE
DETERMINED
BY
ULTRASONOGRAPHY
CAVITAU
383
17
8.2.1
PREOPERATIVE
METHODS
TO
DETERMINE
BONE
MARROW
DEFECTS
IN
JAWBONE
(BMDJ/FDOJ)
383
8.2.1.1
DETERMINING
BMDJ/FDOJ
WITH
CONVENTIONAL
2D-OPGS
383
8.2.1.2
DETERMINING
BMDJ/FDOJ
WITH
3D-CBCT/DVT
384
8.2.1.3
DETERMINING
BMDJ/FDOJ
WITH
CAVITAU
USING
ULTRASOUND
WAVES
384
8.2.2
POSTOPERATIVE
METHODS
TO
DETERMINE
BMDJ/FDOJ
385
8.2.2.1
DETERMINING
BMDJ/FDOJ
WITH
RANTES/CCL5
(RANTES/CCL5)
EXPRESSION
385
8.2.2.2
COLLECTION
OF
PREOPERATIVE
REL-JBD,
HU
AND
CAVITAU
VALUES
AND
POSTOPERATIVELY
MEASURED
LEVELS
OF
RANTES/CCL5
EXPRESSION
IN
A
GROUP
OF
210
PATIENTS
WITH
BMDJ/FDOJ.
385
8.2.3
RESULTS
386
8.2.3.1
COMPARISON
OF
PREOPERATIVE
CAVITAU
AND
HU
VALUES
WITH
POSTOPERATIVE
EVALUATION
OF
RANTES/CCL5
EXPRESSION
IN
A
GROUP
OF
210
PATIENTS
WITH
BMDJ/FDOJ
386
8.2.3.2
COMPARISON
OF
REL-JBD,
HU,
AND
CAVITAU
VALUES
OF
HEALTHY
JAWBONE
388
8.2.3.3
COMPARISON
OF
REL-JBD,
HU,
AND
CAVITAU
VALUES
OF
HEALTHY
JAWBONE
AND
BMDJ/FDOJ
AREAS
389
8.2.3.4
ON
BONE
MARROW
DEFECTS
AND
2D-OPG
390
8.2.3.5
ON
BONE
MARROW
DEFECTS
AND
3D-DVT
390
8.2.4
SUMMARY
AND
CONCLUSION
391
9.
GLOSSARY
393
18
|
| adam_txt |
TABLE
OF
CONTENTS
FOREWORD
BY
DR.
MIGUEL
STANLEY
3
FOREWORD
BY
DR.
JOHANN
LECHNER
5
INTRODUCTION
19
1.
WHAT
ARE
"
BONE
MARROW
DEFECTS
IN
JAWBONE
"
?
23
1.1
DIFFERENT
DEFINITIONS
AND
CLASSIFICATIONS
-
A
PLEA
FOR
PRECISE
TERMINOLOGY
25
1.1.1
MAXILLO-MANDIBULAR
OSTEOIMMUNOLOGY
25
1.1.2
"
NICO
"
AND
FDOJ
25
1.1.3
SUMMARISING
CONCLUSION
28
1.2
MORPHOLOGY
OF
FATTY
DEGENERATIVE
OSTEOLYSIS/OSTEONECROSIS
IN
JAWBONE
30
1.2.1
MACROSCOPIC
FEATURES
OF
BONE
SAMPLES
30
1.2.2
EXTENT
OF
FDOJ
SHOWN
BY
CONTRAST
AGENT
31
1.2.3
PATHOPHYSIOLOGY
AND
CELL
BIOLOGY
OF
FDOJ
33
1.3
HISTOLOGY
OF
FDOJ
35
1.3.1
PATHOHISTOLOGICAL
DEFINITION
OF
FATTY
DEGENERATIVE
OSTEOLYSIS
OF
JAWBONE
35
1.3.2
ADDITIONAL
HISTOLOGIC
STUDIES
AND
CHARACTERIZING
HISTOLOGIC
FINDINGS
ON
FDOJ
CAN
ALSO
BE
FOUND
IN
CHAPTERS
36
1.3.3
PROF.
JE
BOUQUOT
AND
THE
HISTOLOGY
OF
FDOJ
36
1.4
HOW
TO
MEASURE
RANTES/CCL5
IN
FDOJ
SAMPLES?
37
1.4.1
PROCESSING
OF
NECROTIC
TISSUE
SAMPLES
AND
MEASUREMENT
OF
RANTES
IN
FDOJ
SAMPLES
AND
SERUM
37
1.4.2
ANALYSIS
OF
RANTES
IN
SERUM
38
1.5
FDOJ
AND
RANTES/CCL5
-
PARTNERS
OF
INFLAMMATORY
SYSTEMIC
NETWORKING?
38
1.5.1
FDOJ
AS
A
SYSTEMIC
THREAT
THROUGH
RANTES/CCL5
OVEREXPRESSION
39
1.5.2
THE
ROLE
OF
RANTES/CCL5
IN
DISEASES
39
1.5.3
ORIGIN
OF
RANTES/CCL5
IN
FDOJ:
FATTY
TISSUE
AND
ADIPOCYTES
41
1.6
RESULTS
OF
RANTES/CCL5
AND
FGF-2
OVEREXPRESSION
IN
FDOJ 43
1.6.1
RESULTS
OF
PRELIMINARY
RESEARCH
ON
JAWBONE
CYTOKINE
EXPRESSION
43
1.6.2
STUDY
CONCENTRATING
ON
31
FDOJ
AND
3
HEALTHY
JAWBONE
PATIENTS
44
1.6.3
RANTES
IN
JAWBONE
CAVITATIONS
-
ASSIGNED
TO
CLINICAL
DISEASE
45
1.6.4
FGF-2
IN
JAWBONE
CAVITATION
TISSUE
-
ASSIGNED
TO
CLINICAL
DISEASE
46
1.6.5
CHARACTERISTICS
OF
RANTES/CCL5
47
1.6.6
COMPARISON
OF
RANTES
EXPRESSION
IN
FDOJ
TO
RANTES
EXPRESSION
IN
PATHOLOGICAL
BODY
TISSUES
47
7
1.6.7
CHARACTERISTICS
OF
FGF-2
48
1.6.8
COMPARISON
OF
FGF-2
EXPRESSION
IN
FDOJ
WITH
FGF-2
EXPRESSION
IN
PATHOLOGICAL
BODY
TISSUE
49
1.6.8.1
RANTES
AND
FGF-2
AND
THEIR
ROLE
IN
BREAST
CANCER
50
1.6.8.2
RANTES
AND
FGF-2
AND
THEIR
ROLE
IN
RHEUMATOID
ARTHRITIS
51
1.6.8.3
RANTES
AND
FGF-2
AND
THEIR
ROLE
IN
NEURODEGENERATIVE
DISEASES
52
1.6.9
FDOJ
-
A
LOCAL
SITE
OF
CHRONIC
INFLAMMATION
IN
JAWBONE
53
1.6.10
FDOJ
AREAS
-
A
SYSTEMIC
PATHOGENIC
RELEVANT
PHENOMENON
54
1.6.11
SUMMARY
AND
CONCLUSION
54
1.7
DISCUSSION
OF
THE
IMMUNOLOGICAL
RESULTS
57
1.7.1
INFLAMMATORY
AND
PROINFLAMMATORY
MESSENGERS
57
1.7.2
ANTIINFLAMMATORY
MESSENGERS
57
1.7.3
INFLAMMATORY
BALANCE
IN
FDOJ
58
1.7.4
ORIGIN
OF
RANTES/CCL5
IN
FDOJ
58
1.7.5
SYNOPSIS
59
1.8
ASEPTIC-AVASCULAR
OSTEONECROSIS
-
FDOJ
IN
ICD-1
0?
61
1.8.1
LOCAL
"
SILENT
INFLAMMATION
"
IN
THE
JAWBONE
AND
RANTES/CCL5
OVEREXPRESSION
61
1.8.2
METHODS
AND
ANALYSIS
61
1.8.2.1
PCR
DNA
ANALYSIS
OF
THE
EXTRACTED
BONE
SAMPLES
62
1.8.2.2
ANALYSIS
OF
PRESURGICAL
RADIODENSITY
OF
THE
FDOJ
AREA
IN
OPG
62
1.8.2.3
HISTOLOGY
ANALYSIS
OF
24
FDOJ
SAMPLES
63
1.8.2.4
PCR
ANALYSIS
OF
FDOJ
IN
TERMS
OF
BACTERIAL
DNA
63
1.8.2.5
CYTOKINE/CHEMOKINE
ANALYSIS
OF
FDOJ
SAMPLES
64
1.8.2.6
X-RAY
RADIODENSITY
ANALYSIS
OF
FDOJ
AREAS
65
1.8.2.7
CORRELATIONS
BETWEEN
RADIODENSITY
AND
RANTES
LEVELS
IN
FDOJ
SAMPLES
65
1.8.2.8
SUMMARY
OF
RESULTS
66
1.8.3
DISCUSSION
66
1.8.3.1
DISCUSSION
OF
HISTOLOGICAL
RESULTS
66
1.8.3.2
DISCUSSION
OF
RADIODENSITY
WITHIN
THE
FDOJ
AREA
IN
OPG 67
1.8.3.3
DISCUSSION
OF
PCR
ANALYSIS
OF
FDOJ
'
S
BACTERIAL
DNA
68
1.8.3.4
DISCUSSION
OF
THE
CYTOKINE/CHEMOKINE
ANALYSIS
IN
FDOJ
68
1.8.4
SUMMARY
AND
CONCLUSION
69
8
2.
RANTES
UND
SYSTEMIC
DISEASES
73
2.1
PATHOGENETIC
ASPECTS
OF
FDOJ:
APPROACH
TO
A
MEDIATOR-BASED
HYPOTHESIS
OF
SYSTEMIC-CAUSAL
RELATIONS
73
2.1.1
CHEMOKINE
RANTES/CCL5
AS
AN
UNKNOWN
LINK
BETWEEN
WOUND
HEALING
IN
JAWBONE
AND
SYSTEMIC
DISEASE
73
2.1.1.1
RESULTS
OF
SEVEN
CYTOKINE
PANEL
EVALUATIONS
IN
OSTEONECROTIC
AND
HEALTHY
JAWBONE
74
2.1.1.2
EXPRESSION
OF
SEVEN
CYTOKINES
IN
THE
WISDOM
TOOTH
AREA
OF
JAWBONE
IN
16
PATIENTS
WITH
RHEUMATIC
ARTHRITIS
74
2.1.1.3
CASE
REPORT:
RANTES
OVEREXPRESSION
IN
JAWBONE
IN
THE
FORMER
WISDOM
TOOTH
AREA
75
2.1.1.4
EXPRESSION
OF
SEVEN
CYTOKINES
IN
THE
APICAL
AREA
OF
ROOT-FILLED
TEETH
IN
JAWBONE
75
2.1.1.5
CASE
REPORT:
RANTES
OVEREXPRESSION
IN
JAWBONE
UNDERNEATH
A
ROOT-FILLED
TOOTH
76
2.1.1.6
CASE
REPORT:
RECURRING
BREAST
CANCER
AND
COMPARISON
OF
RANTES
OVEREXPRESSION
IN
THE
WISDOM
TOOTH
AREA
AND
IN
JAWBONE
UNDERNEATH
A
ROOT-FILLED
TOOTH
77
2.1.1.7
CONCLUSIONS
78
2.1.2
HYPERACTIVATED
SIGNALING
PATHWAYS
OF
CHEMOKINE
RANTES/CCL5
IN
OSTEOPATHIES
OF
JAWBONE
IN
BREAST
CANCER
PATIENTS
79
2.1.2.1
COHORT
OF
23
BREAST
CANCER
PATIENTS
79
2.1.2.2
RESULTS
OF
7
CYTOKINE
PANEL
EVALUATION
IN
OSTEONECROTIC
AND
HEALTHY
JAWBONE
79
2.1.2.3
THE
ROLE
OF
RANTES
IN
DISEASES
81
2.1.2.4
ROLE
OF
RANTES
IN
BREAST
CANCER
81
2.1.2.5
ORIGIN
OF
RANTES
IN
FDOJ:
FATTY
TISSUE
AND
ADIPOCYTES
82
2.1.2.6
COMPARISON
OF
RANTES
EXPRESSION
IN
FDOJ
TO
RANTES
EXPRESSION
IN
BREAST
CANCER
TISSUES
82
2.1.2.7
RANTES
AND
METASTASIS
OF
BREAST
CANCER
83
2.1.2.8
RANTES/CCL5
IN
SERUM
AND
CORRELATION
TO
BREAST
CANCER
83
2.1.2.9
FDOJ
AND
RANTES
-
PARTNERS
OF
INFLAMMATORY
SYSTEMIC
NETWORKING?
84
2.1.2.10
SYNOPSIS
AND
CONCLUSION
85
2.1.3
CASE
STUDIES
LINKING
SILENT
INFLAMMATION
IN
JAWBONE
WITH
EPISTEMOLOGY
OF
BREAST
CANCER
88
2.1.3.1
CRITICAL
INTERPLAY
OF
JAWBONE
CAVITATIONS
EXPRESSED
RANTES/CCL5
ON
BREAST
CANCER?
88
2.1.3.2
"
SILENT
INFLAMMATION"
IN
JAWBONE:
CLINICAL
FEATURES
OF
FATTY-DEGENERATIVE
OSTEONECROSIS
JAWBONE
-
DEFINITION
AND
DIAGNOSTIC
CRITERIA
88
2.1.3.3
STUDY
PARTICIPANTS:
39
FEMALE
PATIENTS
WITH
BREAST
CANCER
90
2.1.3.4
IMMUNOHISTOCHEMISTRY
OF
RANTES/CCL5
EXPRESSION
IN
FDOJ
90
9
2.1.3.5
MULTIPLEX
ANALYSIS
OF
39
FDOJ
SAMPLES
IN
BREAST
CANCER
CASES
-
RANTES/
CCL5
EXPRESSION
WHEN
COMPARED
TO
HEALTHY
JAWBONE
90
2.1.3.6
CLINICAL
CASES
OF
2
BREAST
CANCER
PATIENTS
-
COMPARISON
OF
X-RAY
DIAGNOSTICS,
RANTES/CCL5
EXPRESSION
AND
LIGHT
MICROSCOPY.
91
2.1.3.7
IMMUNOHISTOCHEMISTRY
AND
STAINING
OF
RANTES/CCL5
EXPRESSION
IN
JAWBONE
IN
TWO
BREAST
CANCER
PATIENTS
93
2.1.3.8
IMMUNOHISTOCHEMISTRY
AND
STAINING
OF
BREAST
CANCER
PREPARATIONS
94
2.1.3.9
RANTES/CCL5
IN
FDOJ
SAMPLES
VERSUS
SERUM
SAMPLES
95
2.1.3.10
ADIPOSE
TISSUE
AND
RANTES/CCL5
IN
OBESITY,
IN
BREAST
CANCER
AND
IN
FDOJ
97
2.1.3.11
THE
ROLE
OF
ADIPOCYTES
AND
RANTES/CCL5
IN
TUMOR
GROWTH
AND
PROLIFERATION
99
2.1.3.12
HIGH
SERUM
LEVELS
OF
RANTES/CCL5
SERVE
AS
INDICATOR
IN
TUMORIGENESIS
AND
PERPETUATE
ANGIOGENESIS
IN
THE
TUMOR
101
2.1.3.13
ADIPOCYTES
IN
TUMOR
AND
IN
FATTY-DEGENERATED
JAWBONE
MARROW
ARE
THE
SOURCE
OF
RANTES/CCL5
EXPRESSION
101
2.1.3.14
RANTES/CCL5
AND
BREAST
CANCER
METASTASIS
102
2.1.3.15
CONCLUSION:
IMMUNE
SYSTEM
-
BONE
INTERACTIONS
IN
THE
NEW
FIELD
OF
"
MAXILLO-MANDIBULAR
OSTEOIMMUNOLOGY
"
102
2.1.4
CASE
REPORTS:
METASTASIS
OF
BREAST
CANCER
ADENOCARCINOMA
IN
JAWBONE/FDOJ
108
2.1.4.1
CASE
#1:
108
2.1.4.2
CASE
#2:
109
2.1.4.3
CONCLUSION
111
2.1.5
PERIPHERAL
NEUROPATHIC
FACIAL/TRIGEMINAL
PAIN
AND
RANTES/CCL5
IN
JAWBONE
CAVITATION
111
2.1.5.1
ETIOLOGY
OF
CHRONIC
FACIAL
PAIN
111
2.1.5.2
PATIENT
COHORT:
15
PATIENTS
WITH
AFP/TRN
112
2.1.5.3
SAMPLING
OF
FDOJ
TISSUE
ON
15
PATIENTS
WITH
AFP/TRN
113
2.1.5.4
RESULTS
113
2.1.5.5
HISTOLOGY
IN
NEUROPATHIC
FACIAL
PAIN
114
2.1.5.6
HYPERACTIVATED
CHEMOKINE
RANTES/CCL5
IN
FDOJ
114
2.1.5.7
IMMUNOLOGY
IN
NEUROPATHIC
FACIAL
PAIN
115
2.1.5.8
OPIOID
RECEPTORS
AND
CHEMOKINE
RANTES/CCL5
116
2.1.5.9
DIAGNOSTIC
PROBLEMS
OF
FDOJ
LESIONS
BY
X-RAY
117
2.1.5.10
CLINICAL
RELEVANCE
OF
FDOJ
SURGERY
IN
AFP/TRN
CASES
118
2.1.5.11
CLINICAL
CASE
OF
FDOJ
SURGERY
119
2.1.5.12
CONCLUSIONS
120
2.1.6
THE
IMPACT
OF
RANTES
FROM
JAWBONE
ON
CHRONIC
FATIGUE
SYNDROME
123
2.1.6.1
METHODS:
21
PATIENTS
WITH
CCHRONIC
FATIGUE
SYNDROME
123
10
2.1.6.2
RESULTS:
21
CHRONIC
FATIGUE
SYNDROME
PATIENTS
124
2.1.6.3
DISCUSSION
125
2.1.6.4
CONCLUSION:
THE
CHRONIC
FATIGUE
SYNDROME
INFLAMMATORY
HYPOTHESIS
126
2.1.7
THE
VITAMIN
D
RECEPTOR
AND
THE
ETIOLOGY
OF
RANTES/CCL-EXPRESSIVE
FATTY-DEGENERATIVE
OSTEOLYSIS
OF
THE
JAWBONE
129
2.1.7.1
AN
INTERFACE
BETWEEN
OSTEOIMMUNOLOGY
AND
BONE
METABOLISM
129
2.1.7.2
STUDY
COHORT
OF
43
PATIENTS
WITH
FDOJ
129
2.1.7.3
SERUM
MEASUREMENT
OF
25D
AND
1
,25D
130
2.1.7.4
CYTOKINE
PROFILE
MEASUREMENT
IN
JAWBONE
OSTEOLYSIS
130
2.1.7.5
DISTRIBUTION
OF
1,25D
AND
25D
IN
THE
TOTAL
COHORT
131
2.1.7.6
THE
RATIO
OF
25-HYDROXY-(CHOLECALCIFEROL)
AND
1
,25-DIHYDROXY-(CALCITRIOL)
VITAMIN
D3
IN
THE
DETERMINATION
OF
A
DEACTIVATED
VITAMIN
D
RECEPTOR
132
2.1.7.7
RANTES
EXPRESSION
AND
THE
VITAMIN
D
RATIO
134
2.1.7.8
SERUM
LEVELS
OF
1
,25D
AND
25D
IN
THE
FDOJ
COHORT
134
2.1.7.9
THE
PHENOMENON
OF
THE
DEACTIVATED
VITAMIN
D
RECEPTOR
135
2.1.7.10
THE
CONNECTION
BETWEEN
DEACTIVATED
VDR
AND
FDOJ:
DISRUPTED
VITAMIN
D
METABOLISM
AND
PATHOLOGICAL
MORPHOLOGY
IN
THE
JAWBONE
135
2.1.7.11
SYSTEMIC
SIGNAL
TRANSDUCTION
BY
HYPERACTIVATED
RANTES/CCL5
FROM
FDOJ
AREAS
136
2.1.7.12
SYSTEMIC
CROSS-LINKING
OF
VDR
DEACTIVATION
AND
OSTEOLYSIS
IN
THE
JAWBONE
137
2.1.7.13
CONCLUSIONS
139
2.2
SALUTOGENETIC
ASPECTS
OF
FDOJ
TREATMENT
IN
COMPLEMENTARY
MEDICAL
PRACTICE
143
2.2.1
CLINICAL
CASE
REPORT
#1:
MALE
PATIENT,
AGE
38:
RHEUMATIC
JOINT
PAIN
143
2.2.1.2
POSTSURGICAL
FINDINGS
AFTER
FDOJ
DEBRIDEMENT
143
2.2.1.3
HISTOLOGICAL
FINDINGS
143
2.2.1.4
EVALUATION
OF
PATHOLOGIC
ANALYSIS
DATA
144
2.2.2
CLINICAL
CASE
REPORT
#1:
MALE
PATIENT,
AGE
39:
ASTHMA
144
2.2.2.1
CLINICAL
SYMPTOMS
144
2.2.2.2
POSTSURGICAL
FINDINGS
AFTER
FDOJ
TREATMENT
144
2.2.2.3
HISTOLOGICAL
FINDINGS
144
2.2.2.4
EVALUATION
OF
PATHOLOGIC
ANALYSIS
DATA
145
2.2.3
CASE
STUDY
LINKING
RANTES/CCL5
OVEREXPRESSION
IN
JAWBONE
WITH
CHEMOKINE
RECEPTORS
IN
THE
CENTRAL
NERVOUS
SYSTEM.
145
2.2.3.1
SILENT
INFLAMMATION
IN
THE
JAW
AND
NEUROLOGICAL
DYSREGULATION
145
2.2.3.2
THE
CLINICAL
CASE:
19-YEAR-OLD
FEMALE
PATIENT
145
2.2.3.3.
SUMMARY
OF
CLINICAL
INVESTIGATIONS,
FINDINGS,
AND
TREATMENTS
146
2.2.3.4
DIAGNOSIS
OF
"SILENT
INFLAMMATION"
IN
THE
JAW
146
11
147
2.2.3.5
HYPERACTIVATED
IMMUNE
MEDIATORS
IN
OSTEOLYTIC
JAWBONE
2.2.3.6
HISTOLOGY
OF
FDOJ
SURGICAL
AREAS
148
2.2.3.7
RESULTS
OF
JAWBONE
REMEDIATION
FROM
MARCH
2010
TO
AUGUST
2010
IN
THE
CASE
OF
RECURRENT
SYNCOPE
148
2.2.3.8
TRANSITION
FROM
ACUTE
WOUND
INFECTION
TO
CHRONIC
INFLAMMATION
150
2.2.3.9
SYSTEMIC
EFFECTS
OF
THE
CHEMOKINE
RANTES/CCL5
151
2.2.3.10
FDOJ
AREAS
BECOME
IMMUNOLOGICALLY
EFFECTIVE
"NEO-SELF
EPITOPES"
151
2.2.3.11
CHEMOKINE-INDUCED
"SILENT
INFLAMMATION"
IN
THE
CENTRAL
NERVOUS
SYSTEM
152
2.2.3.12
CONCLUSION
-
LINK
BETWEEN
THE
JAWBONE
AND
THE
CENTRAL
NERVOUS
SYSTEM
153
2.2.4
CHRONIC
FATIGUE
SYNDROME
AND
"
SILENT
INFLAMMATION
"
OF
THE
JAW
157
2.2.4.1
CASE
STUDY
ON
SUPPLEMENTING
DIAGNOSTIC
DENTAL
X-RAYS
WITH
ULTRASOUND
157
2.2.4.2
RADIOLOGICAL
FINDINGS
WITH
2D-OPG
AND
DVT/CBCT
157
2.2.4.3
TRANS-ALVEOLAR
ULTRASOUND
BONE
DENSITY
MEASUREMENT
158
2.2.4.4
SURGICAL
REPAIR
OF
AREA
38/39
159
2.2.4.5
BONE
MARROW
DEFECT
MORPHOLOGY
160
2.2.4.6
HISTOLOGICAL
FINDINGS
160
2.2.4.7
LOCAL
HYPERACTIVATION
OF
IMMUNE
MEDIATOR
CHEMOKINE
RANTES/CCL5
IN
OSTEOLYTIC
JAWBONE
160
2.2.4.8
CAVITAU
MEASUREMENT
OF
BONE
DENSITY
161
2.2.4.9
RANTES/CCL5
EXPRESSION
IN
CAVIATION
48/49
161
2.2.4.10
FUNGAL
TOXINS
161
2.2.4.11
CONCLUSION
162
2.3.1
OSTEOIMMUNOLOGY
OF
TUMOR
NECROSIS
FACTOR-ALPHA,
LNTERLEUKIN-6,
AND
RANTES/CCL5
165
2.3.1.1
A
REVIEW
OF
KNOWN
AND
POORLY
UNDERSTOOD
INFLAMMATORY
PATTERNS
IN
OSTEONECROSIS
165
2.3.1.2
TNF-A
AND
IL-6
IN
INFLAMMATORY
BONE
DEGRADATION
165
2.3.1.3
BONE
RESORPTION
BY
TNF-A
AND
IL-6
IN
RHEUMATOID
ARTHRITIS
166
2.3.1.4
BONE
RESORPTION
BY
TNF-A
AND
IL-6
IN
OSTEOPOROSIS
167
2.3.1.5
THE
ROLE
OF
TNF-A
AND
IL-6
IN
OBESITY
168
2.3.1.6
THE
ROLE
OF
TNF-A
AND
IL-6
IN
MAXILLO-MANDIBULAR
BONE
RESORPTION
AND
INFLAMMATORY
ORAL
MEDICAL
CONDITIONS
169
2.3.1.7
IN
BONE
RESORPTION
-
EXCEPT
FOR
FDOJ
-
TNF-A
IS
THE
PRIMARY
INFLAMMATORY
CYTOKINE
176
2.3.1.8
CONCLUSION
FDOJ
AS
AN
UNIQUE
INFLAMMATORY
EVENT
177
2.3.2
IMMUNOHISTOLOGICAL
STAINING
OF
UNKNOWN
CHEMOKINE
RANTES/CCL5
EXPRESSION
IN
JAWBONE
MARROW
DEFECTS
182
12
2.3.2.1.
OSTEOIMMUNOLOGY
AND
DISRUPTION
OF
BONE
REMODELING
IN
CLINICAL
CASE
STUDIES
182
2.3.2.2
COMPARISON
OF
X-RAY
DIAGNOSTICS,
RANTES/CCL5
EXPRESSION,
LIGHT
MICROSCOPY,
AND
IMMUNOHISTOCHEMISTRY
IN
SIX
CLINICAL
CASES
185
2.3.2.3
SUMMARY
OF
RESULTS
189
2.3.2.4
CONCLUSIONS
-
"
MAXILLO-MANDIBULAR
OSTEOIMMUNOLOGY
"
-
INTERACTIONS
BETWEEN
BONE
AND
THE
IMMUNE
SYSTEM.
193
3.
DIAGNOSTIC
PROBLEMS
OF
BMDJ/FDOJ
LESIONS
IN
JAWBONE
197
3.1
DETERMINING
BONE
DENSITY
IN
THE
JAW
AND
LOCATION
OF
BONE
MARROW
DEFECTS
199
3.1.1
WHY
IS
A
PANORAMIC
X-RAY
(2D-OPG)
NOT
ENOUGH
FOR
THE
DIAGNOSIS
OF
A
"
BONE
MARROW
DEFECT
"
?
199
3.1.2
OTHER
METHODS
FOR
IMAGING
BONE
STRUCTURES
200
3.1.2.1
COMPUTED
TOMOGRAPHY
200
3.1.2.2
CONE
BEAM
CT/DIGITAL
VOLUME
TOMOGRAPHY
(CBCT/DVT):
201
3.1.2.3
MAGNETIC
RESONANCE
IMAGING
(MRI)
201
3.1.2.4
TECHNETIUM-99M
RADIOISOTOPE
SCINTIGRAPHY
202
3.1.3
CLASSIFICATION
OF
BONE
DENSITY
WITH
HOUNSFIELD
UNITS
202
3.2
VALIDATION
OF
DENTAL
X-RAY
BY
CYTOKINE
RANTES
207
3.2.1
COMPARISON
OF
X-RAY
FINDINGS
WITH
CYTOKINE
RANTES
OVEREXPRESSION
IN
JAWBONE
207
3.2.2
GROUPS
OF
PATIENTS
EXAMINED
207
3.2.3
RELIABILITY
OF
INFORMATION
ON
X-RAY
DENSITY
OF
X-RAY
MACHINE
USED
207
3.2.4
ULTRASOUND
MEASUREMENT
OF
BONE
DENSITY
-
TRANSALVEOLAR
ULTRASOUND
MEASUREMENT
207
3.2.5
REFERENCE
VALUES
FOR
VALIDATING
THE
X-RAY
DENSITY
208
3.2.5.1
IMMUNE
MESSENGERS
AND
X-RAY
DENSITY
OF
HEALTHY
JAWBONE
(N
=
19)
209
3.2.5.2
HYPERACTIVATED
CHEMOKINE
RANTES/CCL5
IN
FDOJ
209
3.2.5.3
MEASUREMENT
OF
JAWBONE
DENSITY
WITH
TRANSALVEOLAR
ULTRASOUND
TECHNOLOGY
(TAU)
210
3.2.5.4
COMPARISON
OF
XRDN
AND
RANTES
EXPRESSION
IN
HEALTHY
JAWBONE
(N
=
19)
AND
FDOJ
(N
=
31)
211
3.2.5.5
COMPARISON
OF
XRDN
AND
FDOJ
USING
CONTRAST
AGENT
212
3.2.5.6
INDIVIDUAL
CASE
COMPARING
PREOPERATIVE
AND
POSTOPERATIVE
2D-OPG
WITH
RANTES/CCL5
EXPRESSION
IN
FDOJ
213
3.2.5.7
COMPARISON
OF
XRDN
IN
CONTROLS
WITH
PREOP/
POSTOP
2D-OPG,
WITH
RANTES
EXPRESSION
AND
WITH
TAU
214
3.2.6
CONCLUSIONS
AND
SUMMARY
215
13
4.
ULTRASOUND
IN
DENTISTRY
FOR
MEASURING
BONE
QUALITY
217
4.1
.FUNDAMENTAL
SUITABILITY
OF
QUANTITATIVE
ULTRASOUND
TRANSMISSION
VELOCITY
217
4.2
NON-INVASIVE
ASSESSMENT
OF
THE
HUMAN
JAWBONE
WITH
ULTRASOUND
WAVES
217
4.3
ULTRASOUND
AND
ASSESSMENT
OF
MECHANICAL
BONE
QUALITY
220
4.4
LITERATURE
ON
ULTRASOUND
AND
CAVITATIONS
AND
OSTEONECROSES
OF
THE
JAWBONE
224
4.5
JAWBONES
AND
IMPLANT
STABILITY
-
LITERATURE
ON
ULTRASOUND
TRANSMISION
VELOCITY
(UTV)
FOR
PROSPECTIVE
REVIEW
228
4.6
COMPARISON
OF
PREVIOUS
CAVITAT
TAU
DEVICE
WITH
NEW
CAVITAU
230
4.6.1
HISTORY
OF
TRANS-ALVEOLAR
ULTRASONOGRAPHY
230
4.6.2
TRANSMISSION
ULTRASONOGRAPHY
WITH
OLD
CAVITAT
231
4.6.3
DISADVANTAGES
OF
CAVITAT
231
4.6.4
DESCRIPTION
OF
NEW
CAVITAU
232
4.6.5
NEW
CAVITAU
TECHNOLOGY
FOR
NON-INVASIVE
ASSESSMENT
OF
THE
HUMAN
JAWBONE
WITH
ULTRASOUND
WAVES
233
4.6.6
CAVITAU
DASHBOARD
DISPLAY
235
4.6.7
DETERMINATION
OF
NUMERICAL
BONE
DENSITY
WITH
CAVITAU
236
4.6.8
SEMI-SOLID
GEL
IN
CAVITAU:
ACOUSTIC
COUPLING
237
4.7
TECHNICAL
FEATURES
OF
CAVITAU
238
4.7.1
HOW
ACCURATE
IS
CAVITAU?
239
4.7.2
ARE
CAVITAU
MEASUREMENTS
REPRODUCIBLE?
244
5.
HOW
TO
USE
CAVITAU
IN
PRAXIS
247
5.1
LATERAL
CONTROL
CAVITAU
MEASUREMENT
249
5.2
VERTICAL
CONTROL
CAVITAU
MEASUREMENT
250
5.2.1
3-STEP
MEASUREMENT
OF
THE
LOWER
JAW
WITH
CAVITAU
250
5.2.2
3-STEP
MEASUREMENT
OF
THE
UPPER
JAW
WITH
CAVITAU
251
5.3
CALIBRATING
CAVITAU
253
5.4
CHECKING
CAVITAU
WHEN
TAKING
MEASUREMENTS
254
5.5
VISUALISATION
OF
WATER
AND
AIR
IN
CAVITAU
254
5.6
VISUALISATION
OF
SOFT
TISSUE
IN
CAVITAU
255
5.7
CAVITAU
ENABLES
THE
DENTIST
TO
IMAGE
THE
JAWBONE
WITHOUT
RADIATION
EXPOSURE
259
5.7.1
WHAT
IS
THE
ALARA
PRINCIPLE?
259
5.7.2
WHY
ALARA
PRINCIPLE
IN
DENTISTRY?
260
5.8
CAVITAU
AND
THE
ALARA
PRINCIPLE
IN
THE
DIAGNOSIS
OF
BMDJ
/
FDOJ
I
AOJ
261
5.9
CAVITAU
AND
THE
ALARA
PRINCIPLE
IN
MONITORING
TREATMENT
RESULTS
AND
OPTIMAL
WOUND
HEALING
OF
BMDJ
/
FDOJ
/
AOJ
261
14
6.
WHY
IS
CAVITAU
NECESSARY
IN
DENTISTRY?
263
6.0
WHY
USE
CAVITAU
IN
PRACTICE?
264
6.1
CAVITAU
DISPLAYS
JAWBONE
AREAS
WITH
REDUCED
MINERALISATION
DENSITY
-
265
6.1.1
WHY
WAS
CAVITAU
USED
IN
THESE
SEVEN
CLINICAL
CASES?
265
6.1.2
INDIVIDUAL
EXAMPLES
WITH
RANTES/CCL5
OVEREXPRESSION
271
6.1.3
CAVITAU
SHOWS
AREAS
WITH
IMPAIRED
WOUND
HEALING
276
6.1.4
CAVITAU
SHOWS
AREAS
WITH
OPTIMAL
WOUND
HEALING
276
6.2
IMPLANT
SURGERY,
BONE
MARROW
DEFECTS
IN
THE
JAW
AND
TAU
-
IMPLANT
SUCCESS
WITH
CAVITAU
278
6.2.1
QUESTION
#1
ON
IMPLANT
INSERTION:
IS
THE
JAWBONE
READY
FOR
IMPLANT
INSERTION?
278
6.2.2
QUEST
FOR
ROUTINE
IMPLANT
PRACTICE
AND
CAVITAU
279
6.2.3
THE
PROBLEM:
DETERMINING
THE
BONE
QUALITY
WITH
X-RAY
TECHNIQUES:
A
CRITICAL
OVERVIEW
279
6.2.4
THE
SOLUTION:
DETERMINING
IF
THE
BONE
BEDDING
IS
SECURE
WITH
ULTRASOUND
CAVITAU
280
6.2.5
SUMMARISING
THE
MEDICAL
SIGNIFICANCE
OF
CAVITAU
FOR
IMPLANT
INSERTION
IN
THE
JAW:
HOW
TO
FORECAST
THE
SUCCESS
OF
DENTAL
IMPLANTS?
281
6.2.6
QUESTION
#1
ON
IMPLANT
INSERTION:
DOES
CAVITAU
DISPLAY
LOAD-FREE
JAWBONES
FOR
NON
PROBLEMATIC
AND
DURABLE
IMPLANT
INSERTION?
282
6.2.7
QUESTION
#2
ON
IMPLANT
INSERTION:
SHOULD
I
PLACE
IMPLANTS
IN
POORLY
HEALED
JAWBONES?
284
6.2.8
QUESTION
#3
ON
IMPLANT
INSERTION:
WHY
DO
IMPLANTS
FAIL?
285
6.2.9
QUESTION
#4
ON
IMPLANT
INSERTION:
IS
THERE
A
CONNECTION
BETWEEN
IMPLANT
INSERTION
AND
OCCURRENCE
OF
FDOJ?
287
6.2.9.1
CLINICAL
EXAMPLE:
CAN
THE
RANTES/CCL5
EXPRESSION
BE
RESPONSIBLE
FOR
MULTIPLE
PATIENT
ALLERGIES?
287
6.2.9.2
WHY
DOES
FDOJ
DEVELOP
AROUND
IMPLANTS?
288
6.2.9.3
CAVITAU
DETECTS
FOCAL
INFLAMMATION
AREAS
AROUND
IMPLANTS
THAT
CANNOT
BE
IDENTIFIED
BY
X-RAYS.
290
6.2.10
QUESTION
#5
ON
IMPLANT
INSERTION:
ARE
THERE
AREAS
OF
BONE
AROUND
IMPLANTS
WITH
SPECIFIC
SYSTEMICALLY
RELEVANT
IMMUNE
OR
CYTOKINE
PATTERNS?
293
6.2.10.1
WHY
IS
THIS
PHENOMENON
A
MYSTERY
IN
DENTISTRY?
294
6.2.10.2
WHERE
IS
THE
LINK
BETWEEN
RANTES/CCL5
OVEREXPRESSION
IN
FDOJ
TO
SYSTEMIC
DISEASES?
294
6.2.10.3
IMPLANT
INSERTION
AND
POSSIBLE
CYTOKINE
CASCADES
295
6.2.10.4
CONCLUSIONS
297
6.2.11
RANTES/CCL5
EXPRESSION
IN
20
CASES
WITH
TITANIUM
IMPLANTS
297
6.2.12
CASE
REPORTS
ON
CHRONIC
INFLAMMATION
AROUND
IMPLANTS
AND
CAVITAU
VISUALISATION
298
6.3
ENDODONTICS
AND
CAVITAU
314
6.3.1
IS
ENDODONTIC
TREATMENT
ALWAYS
SAFE?
314
15
6.3.2
CASE
REPORTS
OF
ENDODONTICS
AND
CAVITAU
315
6.3.2.1
CASE
#1:
THE
FIRST
CASE
PERFECTLY
ILLUSTRATES
THE
REQUIREMENT
FOR
A
RADIATION-FREE
METHOD
FOR
OBTAINING
A
VISUAL
REPRESENTATION
OF
THE
MEDULLARY
BONE
DENSITY
IN
PRACTICE.
315
6.3.2.2
CASE
#2:
CAVITAU
SHOWS
OSTEOLYTIC
INTRA
RADICULAR
SEPTA
316
6.3.2.3
CASE
#3:
PATIENT
WITH
RECURRENT
BREAST
CANCER
316
6.3.2.4
CASE
#4:
VISUALISATION
OF
CIRCO-RADICULAR
OSTEOLYSIS/OSTEONECROSIS
WITH
CONTRAST
MED
I
U
M
317
6.3.2.5
CASE
#5:
FEMALE
PATIENT,
HAS
SUFFERED
FROM
FATIGUE
AND
DEPRESSION
FOR
10
YEARS.
318
6.3.2.6
CASE
#6:
THREE
VERTICAL
COMPARATIVE
MEASUREMENTS
319
6.3.2.7
CASE
#7:
THREE
VERTICAL
COMPARATIVE
MEASURING
STEPS
320
6.3.2.8
CASE
#8:
ROOT
FILLING
WITH
PERSISTENT
APICAL
PAIN
320
6.3.2.9
CASE
#9:
DVT/CBCT
DID
NOT
SHOW
ANY
FINDINGS
IN
CHRONIC
PAIN
321
6.4
CAVITAU
FOR
METALLIC
FOREIGN
BODIES
IN
THE
JAW
322
6.4.1
CAVITAU
SHOWS
THE
INFLAMMATORY
EFFECTS
OF
DIFFUSED
METAL
IONS
322
6.4.2
MERCURY
DIFFUSES
INTO
THE
JAWBONE:
A
SCIENTIFIC
STUDY
BY
THE
UNIVERSITY
OF
VIENNA
325
6.5
BONE
REGENERATION,
BONE
GRAFTING
AND
CAVITAU
326
6.5.1
CASE
#1:
MEDICAL
HISTORY:
CHRONIC
BRONCHITIS,
CHRONIC
PAIN
IN
THE
LEFT
MAXILLARY
SINUS
WITH
MORNING
SPUTUM.
326
6.5.2
CASE
#2:
MALE
PATIENT,
49
YEARS
OLD:
"
SMALL
FIBRE
NEUROPATHY"
WITH
CONSTANT
BURNING
FEELING
IN
HANDS
AND
FEET.
330
6.6
OSTEONECROSIS
OF
THE
JAW
BEYOND
BISPHOSPHONATES:
ARE
THERE
ANY
UNKNOWN
LOCAL
RISK
FACTORS?
332
6.6.1
RESEARCH
QUESTION
332
6.6.2
MATERIAL
AND
METHODS
332
6.6.3
BISPHOSPHONATES
AND
ANTITUMOR
THERAPY
333
6.6.3.1
BISPHOSPHONATES
AND
MESENCHYMAL
STEM
CELLS
333
6.6.3.2
BISPHOSPHONATES
AND
ANTI-ANGIOGENESIS
333
6.6.4
OSTEOIMMUNOLOGICAL
PARAMETERS
OF
AIOJ/BMD/FDOJ
AND
BRONJ
WITH
THE
SAME
IMPACT
IN
RESPONSE
TO
BPS
334
6.6.4.1
RANTES/CCL5:
OVEREXPRESSION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
334
6.6.4.2
ISCHEMIA
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
335
6.6.4.3
OSTEOBLAST
ACTIVATION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
336
6.6.4.4
OSTEOCLAST
DEACTIVATION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
337
16
6.6.4.5
ALKALINE
PHOSPHATASE
REDUCTION
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
337
6.6.5
OSTEOIMMUNOLOGICAL
PARAMETERS
OF
AIOJ/BMD/FDOJ
AND
BRONJ
WITH
REVERSED
EFFECTS
AFTER
BP
TREATMENT
338
6.6.5.1
RANKL
DISORDER
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
338
6.6.5.2
OSTEOPROTEGERIN
DISORDER
AS
A
COMMON
OSTEOIMMUNOLOGICAL
CHARACTERISTIC
OF
BRONJ
AND
AIOJ/BMD/FDOJ
338
6.6.5.3
COMMON
DIAGNOSTIC
PARAMETERS
OF
AIOJ/BMD/FDOJ
AND
BRONJ
339
6.6.5.4
HISTOPATHOLOGY
AS
A
COMMON
FEATURE
OF
BRONJ
AND
AIOJ/BMD/FDOJ
339
6.6.6
CASE
DESCRIPTION
OF
AIOJ/BMD/FDOJ
AND
NON-EXPOSED
BRONJ.
339
6.6.7
DISCUSSION
340
6.6.8
CONCLUSION
342
7.
WHY
IS
CAVITAU
IMPORTANT
FOR
SYSTEMIC
DISEASES?
345
7.1
TRIGEMINAL
NEURALGIA,
ATYPICAL
FACIAL
PAIN
AND
CAVITAU
346
7.1.1
TO
SET
THE
MOOD:
"
PROBABLY
THE
MOST
PAINFUL
CONDITION
IN
THE
WORLD
"
346
7.1.2
LITERATURE
ON
THE
MEDICAL
IMPORTANCE
OF
TAU
IN
THE
DIAGNOSIS
AND
TREATMENT
OF
TRIGEMINAL
NEURALGIA
AND
ATYPICAL
FACIAL
PAIN
347
7.1.3
CASE
REPORTS
OF
TRIGEMINAL
NEURALGIA/
ATYPICAL
FACIAL
PAIN
AND
CAVITAU
348
7.2
NEURODEGENERATIVE
DISEASES
AND
CAVITAU
358
7.2.1
NEURODEGENERATIVE
DISEASES:
AMYOTROPHIC
LATERAL
SCLEROSIS,
RANTES/CCL5
AND
CAVITAU
360
7.2.2
NEURODEGENERATIVE
DISEASES:
MULTIPLE
SCLEROSIS
(MS)
AND
CAVITAU
365
7.3
CHRONIC
FATIGUE
SYNDROME
AND
CAVITAU
368
7.3.1
CHRONIC
FATIGUE
SYNDROME
AND
HYPERACTIVATED
IMMUNE
SIGNALS
RANTES/CCL5
FROM
THE
JAWBONE:
SCIENTIFIC
STUDY
368
7.3.2
CAVITAU
CASE
REPORTS
AND
CHRONIC
FATIGUE
SYNDROME
374
7.3.2.1
CASE
#1:
REDUCING
CHRONIC
FATIGUE
TO
AN
ALMOST
"
NORMAL"
LEVEL
374
8.
PUBLISHED
PAPERS
ON
CAVITAU
377
8.1
ULTRASOUND
SONOGRAPHY
CAVITAU
TO
DETECT
FOCAL
OSTEOPOROTIC
JAWBONE
MARROW
DEFECTS
377
8.1.1
METHODS
FOR
VALIDATION
OF
CAVITAU
MEASUREMENTS
377
8.1.2
COMPARISON:
CAVITAU
VS
HISTOLOGY
OF
BMD/FDOJ
377
8.1.3
COMPARISON:
CAVITAU
IN
FATTY
DEGENERATIVE
OSTEOLYSIS
(IN
JAWBONE
WITH
REDUCED
BONE
DENSITY)
VERSUS
LOCAL
RANTES/CCL5
OVEREXPRESSION
378
8.2
FOCAL
BONE
MARROW
DEFECTS
IN
THE
JAWBONE
DETERMINED
BY
ULTRASONOGRAPHY
CAVITAU
383
17
8.2.1
PREOPERATIVE
METHODS
TO
DETERMINE
BONE
MARROW
DEFECTS
IN
JAWBONE
(BMDJ/FDOJ)
383
8.2.1.1
DETERMINING
BMDJ/FDOJ
WITH
CONVENTIONAL
2D-OPGS
383
8.2.1.2
DETERMINING
BMDJ/FDOJ
WITH
3D-CBCT/DVT
384
8.2.1.3
DETERMINING
BMDJ/FDOJ
WITH
CAVITAU
USING
ULTRASOUND
WAVES
384
8.2.2
POSTOPERATIVE
METHODS
TO
DETERMINE
BMDJ/FDOJ
385
8.2.2.1
DETERMINING
BMDJ/FDOJ
WITH
RANTES/CCL5
(RANTES/CCL5)
EXPRESSION
385
8.2.2.2
COLLECTION
OF
PREOPERATIVE
REL-JBD,
HU
AND
CAVITAU
VALUES
AND
POSTOPERATIVELY
MEASURED
LEVELS
OF
RANTES/CCL5
EXPRESSION
IN
A
GROUP
OF
210
PATIENTS
WITH
BMDJ/FDOJ.
385
8.2.3
RESULTS
386
8.2.3.1
COMPARISON
OF
PREOPERATIVE
CAVITAU
AND
HU
VALUES
WITH
POSTOPERATIVE
EVALUATION
OF
RANTES/CCL5
EXPRESSION
IN
A
GROUP
OF
210
PATIENTS
WITH
BMDJ/FDOJ
386
8.2.3.2
COMPARISON
OF
REL-JBD,
HU,
AND
CAVITAU
VALUES
OF
HEALTHY
JAWBONE
388
8.2.3.3
COMPARISON
OF
REL-JBD,
HU,
AND
CAVITAU
VALUES
OF
HEALTHY
JAWBONE
AND
BMDJ/FDOJ
AREAS
389
8.2.3.4
ON
"BONE
MARROW
DEFECTS"
AND
2D-OPG
390
8.2.3.5
ON
"BONE
MARROW
DEFECTS"
AND
3D-DVT
390
8.2.4
SUMMARY
AND
CONCLUSION
391
9.
GLOSSARY
393
18 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Lechner, Johann 1948- Stanley, Miguel |
| author_GND | (DE-588)128669268 |
| author_facet | Lechner, Johann 1948- Stanley, Miguel |
| author_role | aut aut |
| author_sort | Lechner, Johann 1948- |
| author_variant | j l jl m s ms |
| building | Verbundindex |
| bvnumber | BV048312936 |
| ctrlnum | (OCoLC)1335401105 (DE-599)DNB1249943485 |
| edition | 1. Auflage |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02632nam a22005898c 4500</leader><controlfield tag="001">BV048312936</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20221107 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">220705s2022 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,N04</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1249943485</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783931351458</subfield><subfield code="c">Broschur : EUR 68.00 (DE), EUR 70.00 (AT)</subfield><subfield code="9">978-3-931351-45-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3931351459</subfield><subfield code="9">3-931351-45-9</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783931351458</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1335401105</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1249943485</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lechner, Johann</subfield><subfield code="d">1948-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)128669268</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases</subfield><subfield code="b">Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology</subfield><subfield code="c">Dr. Dr. (PhD) Johann Lechner, Dr. Miguel Stanley</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">München</subfield><subfield code="b">Dr. Dr. (Phd-UCN) J. Lechner</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="264" ind1=" " ind2="0"><subfield code="a">Furth bei Landshut</subfield><subfield code="b">MDV Maristen Druck & Verlag GmbH</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">398 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">28 cm x 21 cm, 1626 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"A guide to JawBone Detox" - Umschlag</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Knochennekrose</subfield><subfield code="0">(DE-588)4164292-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kiefer</subfield><subfield code="g">Anatomie</subfield><subfield code="0">(DE-588)4030457-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Ultraschalldiagnostik</subfield><subfield code="0">(DE-588)4061557-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Osteolyse</subfield><subfield code="0">(DE-588)4210410-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Entzündung</subfield><subfield code="0">(DE-588)4014975-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Radiation-free imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ultrasonography</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Entzündung</subfield><subfield code="0">(DE-588)4014975-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Kiefer</subfield><subfield code="g">Anatomie</subfield><subfield code="0">(DE-588)4030457-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Osteolyse</subfield><subfield code="0">(DE-588)4210410-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Knochennekrose</subfield><subfield code="0">(DE-588)4164292-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Ultraschalldiagnostik</subfield><subfield code="0">(DE-588)4061557-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stanley, Miguel</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">MDV Maristen Druck & Verlag GmbH</subfield><subfield code="0">(DE-588)1065494211</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1249943485/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033692453&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033692453</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">vlb</subfield><subfield code="d">20220120</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#vlb</subfield></datafield></record></collection> |
| id | DE-604.BV048312936 |
| illustrated | Illustrated |
| index_date | 2024-07-03T20:10:12Z |
| indexdate | 2024-07-10T09:34:59Z |
| institution | BVB |
| institution_GND | (DE-588)1065494211 |
| isbn | 9783931351458 3931351459 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033692453 |
| oclc_num | 1335401105 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-12 |
| owner_facet | DE-19 DE-BY-UBM DE-12 |
| physical | 398 Seiten Illustrationen 28 cm x 21 cm, 1626 g |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Dr. Dr. (Phd-UCN) J. Lechner |
| record_format | marc |
| spelling | Lechner, Johann 1948- Verfasser (DE-588)128669268 aut Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology Dr. Dr. (PhD) Johann Lechner, Dr. Miguel Stanley 1. Auflage München Dr. Dr. (Phd-UCN) J. Lechner [2022] Furth bei Landshut MDV Maristen Druck & Verlag GmbH [2022] © 2022 398 Seiten Illustrationen 28 cm x 21 cm, 1626 g txt rdacontent n rdamedia nc rdacarrier "A guide to JawBone Detox" - Umschlag Knochennekrose (DE-588)4164292-2 gnd rswk-swf Kiefer Anatomie (DE-588)4030457-7 gnd rswk-swf Ultraschalldiagnostik (DE-588)4061557-1 gnd rswk-swf Osteolyse (DE-588)4210410-5 gnd rswk-swf Entzündung (DE-588)4014975-4 gnd rswk-swf Radiation-free imaging Ultrasonography Entzündung (DE-588)4014975-4 s Kiefer Anatomie (DE-588)4030457-7 s Osteolyse (DE-588)4210410-5 s Knochennekrose (DE-588)4164292-2 s Ultraschalldiagnostik (DE-588)4061557-1 s DE-604 Stanley, Miguel Verfasser aut MDV Maristen Druck & Verlag GmbH (DE-588)1065494211 pbl B:DE-101 application/pdf https://d-nb.info/1249943485/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033692453&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p vlb 20220120 DE-101 https://d-nb.info/provenance/plan#vlb |
| spellingShingle | Lechner, Johann 1948- Stanley, Miguel Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology Knochennekrose (DE-588)4164292-2 gnd Kiefer Anatomie (DE-588)4030457-7 gnd Ultraschalldiagnostik (DE-588)4061557-1 gnd Osteolyse (DE-588)4210410-5 gnd Entzündung (DE-588)4014975-4 gnd |
| subject_GND | (DE-588)4164292-2 (DE-588)4030457-7 (DE-588)4061557-1 (DE-588)4210410-5 (DE-588)4014975-4 |
| title | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology |
| title_auth | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology |
| title_exact_search | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology |
| title_exact_search_txtP | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology |
| title_full | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology Dr. Dr. (PhD) Johann Lechner, Dr. Miguel Stanley |
| title_fullStr | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology Dr. Dr. (PhD) Johann Lechner, Dr. Miguel Stanley |
| title_full_unstemmed | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology Dr. Dr. (PhD) Johann Lechner, Dr. Miguel Stanley |
| title_short | Cavitational Osteonecrosis in Jawbone – From neglected local inflammation to endangering systemic diseases |
| title_sort | cavitational osteonecrosis in jawbone from neglected local inflammation to endangering systemic diseases ultrasonography cavitau for radiation free imaging in maxillo mandibular osteoimmunology |
| title_sub | Ultrasonography CaviTAU for radiation-free imaging in Maxillo-mandibular Osteoimmunology |
| topic | Knochennekrose (DE-588)4164292-2 gnd Kiefer Anatomie (DE-588)4030457-7 gnd Ultraschalldiagnostik (DE-588)4061557-1 gnd Osteolyse (DE-588)4210410-5 gnd Entzündung (DE-588)4014975-4 gnd |
| topic_facet | Knochennekrose Kiefer Anatomie Ultraschalldiagnostik Osteolyse Entzündung |
| url | https://d-nb.info/1249943485/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033692453&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT lechnerjohann cavitationalosteonecrosisinjawbonefromneglectedlocalinflammationtoendangeringsystemicdiseasesultrasonographycavitauforradiationfreeimaginginmaxillomandibularosteoimmunology AT stanleymiguel cavitationalosteonecrosisinjawbonefromneglectedlocalinflammationtoendangeringsystemicdiseasesultrasonographycavitauforradiationfreeimaginginmaxillomandibularosteoimmunology AT mdvmaristendruckverlaggmbh cavitationalosteonecrosisinjawbonefromneglectedlocalinflammationtoendangeringsystemicdiseasesultrasonographycavitauforradiationfreeimaginginmaxillomandibularosteoimmunology |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis